Data from two phase II studies support multiday dosing of netupitant palonosetron in association w BEAM FEAM conditioning regimens prior to hematopoietic cell transplant An open label RCT also supports multiday dosing of fosaprepitant Studies on repeat do

Data from two phase II studies support multiday dosing of netupitant/palonosetron in association w/ BEAM/FEAM conditioning regimens prior to hematopoietic cell transplant. An open-label RCT also supports multiday dosing of fosaprepitant. Studies on repeat dosing of aprepitant IV emulsion, fosnetupitant, and rolapitant are not available.